46 related articles for article (PubMed ID: 38711253)
1. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
[TBL] [Abstract][Full Text] [Related]
2.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
3. Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
Bae S; Sa S; Park S; Cho BS; Kim HJ
Acta Haematol; 2024; 147(3):352-359. PubMed ID: 37751714
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Ionescu F; David JC; Ravichandran A; Sallman DA; Sweet K; Komrokji RS; Chan O; Kuykendall A; Padron E; Faramand R; Bejanyan N; Khimani F; Elmariah H; Pidala J; Mishra A; Perez L; Nishihori T; Lancet JE
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):400-406. PubMed ID: 38429222
[TBL] [Abstract][Full Text] [Related]
6. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
Berton G; Sedaki B; Collomb E; Benachour S; Loschi M; Mohty B; Saillard C; Hicheri Y; Rouzaud C; Maisano V; Villetard F; Corda ED'; Charbonnier A; Rey J; Hospital MA; Ittel A; Abbou N; Fanciullino R; Dadone-Montaudié B; Vey N; Venton G; Cluzeau T; Alary AS; Garciaz S
Leuk Res; 2024 Jun; 141():107500. PubMed ID: 38636413
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R; Dworkin E; Weiner H; Saygin C; Nawas MT; Drazer MW; DuVall AS; Kosuri S; Thirman MJ; Odenike O; Stock W; Larson RA; Patel AA
Leuk Lymphoma; 2024 Jun; 65(6):864-867. PubMed ID: 38441062
[No Abstract] [Full Text] [Related]
8. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
Kobayashi T; Sato H; Miura M; Fukushi Y; Kuroki W; Ito F; Teshima K; Watanabe A; Fujishima N; Kobayashi I; Kameoka Y; Takahashi N
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782790
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM; Prebet T; Itzykson R; Ramos F; Al-Ali H; Shammo J; Pinto R; Maurillo L; Wetzel J; Musto P; Van De Loosdrecht AA; Costa MJ; Esteves S; Burgstaller S; Stauder R; Autzinger EM; Lang A; Krippl P; Geissler D; Falantes JF; Pedro C; Bargay J; Deben G; Garrido A; Bonanad S; Diez-Campelo M; Thepot S; Ades L; Sperr WR; Valent P; Fenaux P; Sekeres MA; Greil R; Pleyer L
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420120
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax-associated interstitial pneumonitis.
Siddiqui AS
Respir Med Case Rep; 2024; 50():102038. PubMed ID: 38812526
[TBL] [Abstract][Full Text] [Related]
11. Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance.
Yao M; Jiang X; Xiao F; Lv X; Sheng M; Xing W; Bai J; Zhou Y
Cancer Lett; 2024 May; 593():216949. PubMed ID: 38729558
[TBL] [Abstract][Full Text] [Related]
12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
16. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract][Full Text] [Related]
17. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
